OGN

OrganonA

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

Most likely

B+

Bull case

40%

Probability

Target price

$14.00

+4.6% vs current

Base case

40%

Probability

Target price

$13.60

+1.6% vs current

B-

Bear case

20%

Probability

Target price

$9.50

-29.0% vs current

AI sentiment snapshot

Latest data as of 2026-05-29

AI commentary

Headline tone is dominated by the merger announcement and the April 30 Q1 release. With an all-cash acquisition pending, OGN should continue to trade primarily as a merger spread rather than a standalone rerating story. Post-print analyst revisions and target changes are not available in the packet, so confidence remains moderate and coverage is still thin on forward estimate digestion.

RankAlpha Sentiment Codex - 2026-05-29

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-04-30catalystQ1 print confirms the stock is still trading as a merger spreadMedium impact

Organon's first-quarter 2026 release showed revenue of $1.460 billion, diluted EPS of $0.55, adjusted diluted EPS of $0.71, and adjusted EBITDA margin of 28.4%; management also said it will not provide guidance or host quarterly earnings calls while the Sun Pharma transaction is pending [#8-K-2026-04-30].

2026-12-31catalystIf the deal slips, standalone leverage and women's-health erosion reassert themselvesHigh impact

If the transaction were delayed or failed, the standalone case would matter again: women's health revenue fell 16% reported and 19% excluding FX in Q1, and Organon ended March 31, 2026 with about $1.12 billion of cash against $8.57 billion of debt [#10-Q-2026-05-04].

2027-03-31eventSun Pharma approval and close timeline remains the main event gateMedium impact

The announced all-cash acquisition by Sun Pharmaceutical Industries remains subject to customary closing conditions, including regulatory approvals and Organon stockholder approval, with closing expected in early 2027; the share price should stay anchored to how quickly that process advances.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-29 • Updated nightlySource: Internal modelMethodology